| Date | Title | Description | |
|---|---|---|---|
| 23 Feb 2022 | On business and financial situation | The Company releases the press release related to the full year 2021 financial results | Download |
| 23 Feb 2022 | On business and financial situation | The Company releases the full year 2021 financial results presentation | Download |
| 23 Feb 2022 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 22 Feb 2022 | On buy-back programmes | ROVI reports the end of the share buy-back programme, effective as of 3 November 2021, and the launching of a new share buy-back programme, effective as of 23 February 2022. | Download |
| 16 Feb 2022 | On business and financial situation | Moderna and ROVI announced that they expand their long-term collaboration for the manufacture of mRNA medicines over the next ten years | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 04 Jul 2022 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the second quarter of 2022 | Download |
| 30 Jun 2022 | Other relevant information | The Company informs about the dividends payment | Download |
| 16 Jun 2022 | Other relevant information | The Company has agreed to execute the capital reduction approved by the 2022 Ordinary General Meeting to amortize the shares acquired in the framework of the own shares repurchase programs | Download |
| 14 Jun 2022 | Announcement of general shareholders’ meeting | ROVI releases the information related to its General Shareholders Meeting | Download |
| 11 May 2022 | On business and financial situation | The Company releases the press release related to the first quarter 2022 financial result | Download |